SUN-LB79 Efficacy of the Percutaneus Administration, Guided by Ultrasound, of Polidocanol Ablation for Cystic Thyroid Nodules

Introduction: The cystic thyroid nodule is a variant of nodular disease presentation, it can condition compressive symptoms, drainage is an alternative for its management, but it presents an elevated rate of recurrence, injection of ethanol is an alternative for refractory cases but it requires multiple sessions and is not exempt for recurrence, on the other hand, polidocanol may represent a best alternative for treatment. Objective: Determine the efficacy of polidocanol administration for cystic thyroid nodule disease. Study Design: An experimental, prospective, comparative of before and after and analytical study was made. Period and Population: Patients older than 18 years were selected, with diagnosis of cystic thyroid nodule disease in whom drainage was made with subsequent ablation with polidocanol 1%, considering therapeutic efficacy a reduction of at least 50% in regard of initial volume. Results: 39 patients were studied, 33 (84-6%) were women, with an age of 49.0 (15.0) years old. All with palpable nodules, time of identification of 14.1 (11.69) months and a palpable size of 3.53 (2.02) cms. The predominant location was the right lobule (51.3%), 24 (61.5%) referred growth before the procedure conditioning compressive symptoms. The main cystic composition was pure and unique in 20 (51.3%). 10 (25.6%) referred important cosmetic problem/ dysphagia. TSH was 1.73 (1.22) mU/ ml. An initial volume was of 13.99 (11.72) ml and a final volume of 6.6 (12.1) ml, p 0.000 (IC 95% 4.4, 10.2). 3 (7.7%) presented hematoma and 2 (6.1%) pain. Time of follow- up was of 24 weeks. Reduction percentage 78.7 (32). 33 (84.6%) achieved a reduction ≥50% and 21 (53.8%) ≥85% of the initial volume. Conclusion: Polidocanol is effective and safe for cystic thyroid nodule disease treatment, its use should be proposed in patients with this pathology.